No.

Publication Date

Citing Article

1

2026

Chinmoy K. Bose, Sacituzumab Tirumotecan in the Evolving Landscape of Ovarian Cancer Treatment, Indian Journal of Gynecologic Oncology. 2026; 24: 54.  https://doi.org/10.1007/s40944-026-01115-3

2

2024

Whi-An Kwon, Min-Kyung Lee. Evolving Treatment Landscape of Frontline Therapy for Metastatic Urothelial Carcinoma: Current Insights and Future Perspectives, Cancers. 2024; 16: 4078.  https://doi.org/10.3390/cancers16234078

3

2026

Esteban Ciliberti, Marta Nerone, Vincenza Ricco, Hui-Ming Lin, Frederik Marmé, Cristiana Sessa, Isabelle Ray Coquard, Kathleen N. Moore, Ilaria Colombo. Antibody drug conjugates in gynaecological cancers: navigating between opportunities and challenges, eClinicalMedicine. 2026; 103895103895.  https://doi.org/10.1016/j.eclinm.2026.103895

4

2025

S. Cazzamalli, E. Puca, D. Neri. Past, present and future of drug conjugates for cancer therapy, Nature Cancer. 2025; 6: 1494.  https://doi.org/10.1038/s43018-025-01042-w

5

2026

Arantzazu Barquin, Lawrence Kasherman, Stephanie Lheureux, Ainhoa Madariaga. Antibody–drug conjugates in gynecologic cancers, Cancer. 2026; 132: e70417.  https://doi.org/10.1002/cncr.70417

6

2026

Yuting Sheng, Hunter E. Wujcik, Mark R. Wakefield, Yujiang Fang. Poseidon’s Trident: “Divine” Intervention in Cervical Cancer Through Chemoradiation, Immunotherapy, and Antibody–Drug Conjugates, Cancers. 2026; 18: 774.  https://doi.org/10.3390/cancers18050774

7

2026

Gihoon You, Jungwoo Choi, Chorong Yang, Sora Kim, JuYeun Jeon, Kyungjin Park, Yangsoon Lee, Sang Hoon Lee. Expanding the horizons of cancer therapy with next-generation 4-1BB agonists: a review of molecular and clinical strategies to maximize efficacy and ensure safety, mAbs. 2026; 18: 2622746.  https://doi.org/10.1080/19420862.2026.2622746

8

2025

Revu V. L. Narayana, Romi Gupta. Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment, Oncogene. 2025; 44: 2343.  https://doi.org/10.1038/s41388-025-03448-3

9

2026

Huanle Wang, Xueyan Yan, Cong Xia, Danni Chen, Bo Pan, Yinan Zhang, Qianshi Zhang. Antibody–drug conjugates in colorectal cancer: advances in targeted delivery and personalized oncology, Frontiers in Bioengineering and Biotechnology. 2026; 14: 1756741.  https://doi.org/10.3389/fbioe.2026.1756741

10

2026

Nishtha R. Vaghela, Vaishali R. Majithiya, Devesh U. Kapoor, Sangeeta D. Gohel. 2026; 93.  https://doi.org/10.1016/B978-0-443-44000-7.00013-9

11

2025

Matthew V. Holt, Yongchao Dou, Meggie N. Young, Alexander B. Saltzman, Meenakshi Anurag, Jonathan T. Lei, Antrix Jain, Mei Leng, Beom-Jun Kim, Lacey E. Dobrolecki, Stefanie F. Faucher, Sara Savage, Chenwei Wang, Zhiao Shi, Hugo Villanueva, Karoline Kremers, Kyle D. Drinnon, Patricia D. Castro, Michael M. Ittmann, Mehak Mehboob Khatani, Sung Han Kim, Matthew J. Ellis, Bing Zhang, Anna Malovannaya, Seth P. Lerner. Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer, Cell Reports Medicine. 2025; 6: 102255102255.  https://doi.org/10.1016/j.xcrm.2025.102255

12

2026

Penghui Liu, Na Li, Jiwu Guo, Gengyu Tong Zhao, Jizhen Wang, Ziyuan Mou, Jie Mao. Immune checkpoint inhibitor therapy for gastric cancer: current status, therapeutic challenges, and future prospects, Frontiers in Immunology. 2026; 17: 1716934.  https://doi.org/10.3389/fimmu.2026.1716934

13

2026

Aki Inase, Shiro Kimbara, Eli Imamura, Mitch A Phelps, Hironobu Minami. Overcoming resistance to antibody-drug conjugates: mechanisms and emerging strategies, The Oncologist. 2026; 31: oyag020.  https://doi.org/10.1093/oncolo/oyag020